H2 PHARMA acquired by ARDIAN
Context
Ardian Growth acquired a minority stake in H2 Pharma in its inaugural healthcare investment. The partnership was established to support the company's ambitious industrial scaling, with a production target of 100 million units per year. The strategic roadmap focuses on internationalizing the group's footprint within the European market and diversifying its service offering to include regulatory affairs and analytical control. Ardian provides strategic support to leverage H2 Pharma's automated manufacturing processes and R&D capabilities, aiming to strengthen its position as a preferred CDMO partner for international pharmaceutical laboratories.
H2 PHARMA, which reported an EBITDA margin of [members only] in 2019, is valued in this transaction at an EV/EBITDA multiple of [members only], to compare with the average currently observed in the Healthcare & Pharma sector (14.3x).
-> Deep-dive in Healthcare & Pharma market trends
Target
Founded in 2009, H2 Pharma is a leading French specialist in the design and production of non-sterile liquid generic and OTC medicines (mouthwashes, syrups, oral solutions). A key partner for major pharmaceutical laboratories, the company controls the entire value chain, from R&D and Marketing Authorization (AMM) filings to automated production and regulatory affairs.
Ent. Value
€25–50M
Equity Value
[members only]
Multiples
EV / Revenue
[members only]
EV / EBITDA
[members only]
EV / EBIT
[members only]
Historical Financials (EUR)
Similar deals in Life Sciences
Similar deals in Life Sciences
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 01/2021 | ARDIAN / BNP PARIBAS DEVELOPPEMENT | PROTEOR | FRANCE | Implants & Prosthetics |
| 11/2020 | NOVALPINA CAPITAL | LABORATOIRE X.O | FRANCE | Generics / Labs |
| 10/2020 | SULZER | HASELMEIER | SWITZERLAND | Medical Consumables |
| 09/2020 | EQT PARTNERS | SCHÜLKE | GERMANY | Medical Consumables |
| 09/2020 | PERMIRA | NEURAXPHARM | GERMANY | Generics / Labs |
| 09/2020 | PATRICIA INDUSTRIES | ADVANCED INSTRUMENTS | UNITED STATES | Diagnostic Equipment |
| 06/2020 | AVISTA CAPITAL PARTNERS | VISION HEALTHCARE | BELGIUM | Nutrition & Dietary Supplements |
| 04/2020 | AMERICAN SECURITIES | PARAGON MEDICAL | UNITED STATES | Medical Devices |
| 04/2020 | WARBURG PINCUS | POLYPLUS | FRANCE | R&D Biotech |
| 04/2020 | ROYAL DSM | GLYCOM | DENMARK | Nutrition & Dietary Supplements |
Other operations with ARDIAN
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 07/2026 | ARDIAN | Munich Electrification | GERMANY | Batteries & EV Tech |
| 07/2026 | ARDIAN | Pflegia | GERMANY | Recruitment / Headhunting |
| 07/2026 | ARDIAN / EURAZEO / UBS | HR PATH | FRANCE | ERP, HR & Finance |
| 01/2026 | ARDIAN | IVB Wellness Lab | SPAIN | Nutrition & Dietary Supplements |
| 12/2025 | ARDIAN | Fermax | SPAIN | Safety & Security |
| 07/2025 | ARDIAN | Dovida | SWITZERLAND | Outpatient Care |
| 05/2025 | ARDIAN | MasterGrid | FRANCE | Electrical |
| 03/2025 | ARDIAN | AKUO | FRANCE | Renewables |
| 03/2025 | ARDIAN | DIOT-SIACI | FRANCE | Brokerage |
| 01/2025 | ARDIAN / EURAZEO / ASTORG | SYCLEF | FRANCE | HVAC (Heating/AC) |
REFERENCES
Revenue range: €25–50M
Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of H2 PHARMA by ARDIAN are reserved for mynth community members. Register for free to unlock full data.
Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.
Press release: view release
Acquirer: ardian